Abstract
The present study examined effects of selective antagonists of D-1 and D-2 dopamine receptors on the development of behavioral sensitization produced by repeated methamphetamine (MAP) administration. Male Sprague-Dawley rats were divided into four groups. Each group received a daily injection of saline (control group), 4 mg/kg MAP (MAP group), 1 mg/kg YM-09151-2 plus 4 mg/kg MAP (YM+MAP group) or 0.5 mg/kg SCH 23390 plus 4 mg/kg MAP (SCH+MAP group) for 14 days. During daily injection for 14 days, the MAP group exhibited a progressive augmentation in locomotor and stereotyped behavior, whereas the progression of such behaviors in the YM+MAP and SCH+MAP group was completely prevented. After an abstinence period of 7 days, all groups received a challenge of 2 mg/kg MAP. The MAP challenge reproduced hyperlocomotion and intense stereotyped behavior only in the MAP group. However, neither the YM+MAP group nor the SCH+MAP group showed sterotypy. The manner in which both groups showed only hyperlocomotion was similar to that observed in the control group. These results indicate that both selective D-1 antagonists and selective D-2 antagonists not only reverse MAP-induced motor effects at each injection but also prevent the development of behavioral sensitization induced by repeated MAP administration.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Akiyama K, Sato M, Otsuki S (1982) Increased 3H-spiperone binding sites in mesolimbic area related to methamphetamine-induced behavioral hypersensitivity. Biol Psychiatry 17:223–231
Angrist B, Lee HK, Gershon S (1974) The antagonism of amphetamine induced symptomatology by a neuroleptic. Am J Psychiatry 131:817–819
Billard W, Ruperto V, Crosby G, Iorio LC, Barnett A (1984) Characterization of the binding of 3H-SCH 23390, a selective D-1 receptor antagonist ligand, in rat striatum. Life Sci 35:1885–1893
Christensen AV, Arnt J, Hyttel J, Larsen J-J, Svendsen O (1984) Pharmacological effects of a specific dopamine D-1 antagonist SCH 23390 in comparison with neuroleptics. Life Sci 34:1529–1540
Creese I, Chen A (1985) Selective D1 dopamine receptor increase following chronic treatment with SCH 23390 Eur J Pharmacol 109:127–128
Ellinwood EH, Sudilovski A, Nelson LJ (1973) Evolving behavior in the clinical and experimental amphetamine (model) psychosis. Am J Psychiatry 130:1088–1093
Espelin DE, Done HK (1968) Amphetamine poisoning: effectiveness of chlorpromazine. N Engl J Med 278:1361–1365
Hyttel J (1983) SCH 23390—The first selective dopamine D-1 antagonist. Eur J Pharmacol 91:153–154
Ichikawa J, Koyama T, Mikuni M, Yamashita I (1986) Effect of methampetamine on presynaptic regulation of monoaminergic neural transmission: in vivo brain dialysis. Bull Jpn Neurochem Soc 25:280–282 (in Japanese)
Iorio LC, Barnett A, Leitz FH, Houser VP, Korduba CA (1983) SCH 23390, a potential benzazepine antipsychotic with unique interaction on dopaminergic systems. J Pharmacol Exp Ther 226:462–468
Jenner P, Marsden CD (1981) Substituted benzamide drugs as selective neuroleptic agents. Neuropharmacology 20:1285–1293
Kashihara K, Fujiwara Y, Sato M (1984) Continuous suppression of methamphetamine-induced supersensitivity by chronic haloperidol administration. Psychiatr Neurol Jpn 86:928–932 (in Japanese)
Kasiwabara K, Akiyama T, Sato M, Otsuki S (1984) Effect of haloperidol, sulpiride and caeruletide on methamphetamine-induced abnormal behaviors in animals. Jpn J Neuropsychopharmacol 6:181–189 (in Japanese)
Kazahaya Y, Akimoto K, Otsuki S (1989) Subchronic methamphetamine treatment enhances methamphetamine-or cocaineinduced dopamine efflux in vivo. Biol Psychiatry (in press)
Mailman RB, Schulz DW, Lewis MH, Staples L, Rollema H, Dehaven DL (1984) SCH 23390: a selective D-1 dopamine antagonist with potent D-2 behavioral actions. Eur J Pharmacol 101:159–160
Nelson L, Ellison G (1978) Enhanced stereotypies after repeated injections but not continuous amphetamines. Neuropharmacology 17:1081–1084
Nishikawa T, Mataga N, Takashima M, Toru M (1983) Behavioral sensitization and relative hyperresponsiveness of striatal and limbic dopaminergic neurons after repeated methamphetamine treatment Eur J Pharmacol 88:190–203
Niznik HB, Grigoriadis DE, Pri-Bar I, Buchman O, Seeman P (1985) Dopamine D2 receptor selectively labeled by a benzamide neuroleptic: [3H]-YM-09151-2. Naunyn-Schmiedeberg's Arch Pharmacol 329:333–343
Peroutka SJ, Snyder SH (1980) Relationship of neuroleptic drug effects at brain dopamine, serotonin, α-adrenergic, and histamine receptors to clinical potency. Am J Psychiatry 137:1518–1522
Porceddu ML, Ongini E, Biggio G (1985) [3H]SCH 23390 binding sites increase after chronic blockade of D-1 dopamine receptors. Eur J Pharmacol 118:367–370
Pugh MT, O'Boyle KM, Molloy AG, Waddington JL (1985) Effects of the putative D-1 antagonist SCH 23390 on stereotyped behaviour induced by the D-2 agonist RU 24213. Psychopharmacology 87:308–312
Robinson TE, Becker JB (1986) Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res Rev 11:157–198
Sato M (1979) An experimental study of onset and relapse mechanisms of the chronic methamphetamine psychosis. Psychiatr Neurol Jpn 81:21–32 (in Japanese)
Sato M, Chen C-C, Akiyama K, Otsuki S (1983) Acute exacerbation of paranoid psychotic state after long-term abstinence in patients with previous methamphetamine psychosis. Biol Psychiatry 18:429–440
Schulz DW, Wyricke SD, Mailman RB (1985) [3H]SCH 23390 has the characteristics of a dopamine receptor ligand in the central neurons system. Eur J Pharmacol 106:211–212
Segal DS, Mandell AJ (1974) Long-term administration of d-amphetamine: progressive augmentation of motor activity and stereotypy. Pharmacol Biochem Behav 2:249–255
Segal DS, Janowsky DS (1978) Psychostimulant-induced behavioral effects: possible models of schizophrenia. In: Lipton MA, DiMascio A, Killam KF (eds) Psychopharmacology: a generation of progress. Raven Press, New York, pp 1113–1123
Shuster L, Yu G, Bates A (1977) Sensitization to cocaine stimulation in mice. Psychopharmacology 52:185–190
Sonsalla PK, Gibb JW, Hanson GR (1986) Roles of D1 and D2 dopamine receptor subtypes in mediating the methamphetamine-induced changes in monoamine systems. J Pharmacol Exp Ther 238:932–937
Terai M, Usuda S, Kuroiwa I, Noshiro O, Maeno H (1983) Selective binding of YM-09151-2, a new potent neuroleptic, to D2-dopaminergic receptors. Upn J Pharmacol 33:749–755
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ujike, H., Onoue, T., Akiyama, K. et al. Effects of selective D-1 and D-2 dopamine antagonists on development of methamphetamine-induced behavioral sensitization. Psychopharmacology 98, 89–92 (1989). https://doi.org/10.1007/BF00442011
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00442011